Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 702 across all filing types
Latest filing 2026-06-04 Proxy Solicitation & In…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-06-04 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-04 English
8-K
Regulatory Filings Classification · 62% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically providing notice of the date change for the company’s 2026 Annual Meeting of Stockholders and detailing deadlines for shareholder proposals and nominations. It is not the full proxy statement itself, nor is it reporting actual voting results, dividends, financial performance, or an audit. It serves as a regulatory announcement without substantive financial data or proxy materials. This falls into the miscellaneous SEC filing category (Regulatory Filings) rather than any of the more specific report types.
2026-05-19 English
10-K/A - Decoy Therapeutics Inc. (0001615219) (Filer)
Annual Report FY 2025
2026-04-30 English
S-8 - Decoy Therapeutics Inc. (0001615219) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form S-8 filing fee calculation table related to the registration of securities under equity incentive plans. It includes detailed fee calculations for newly registered securities, referencing specific SEC rules (Rule 457(c) and Rule 457(h)) and the Securities Act of 1933. The content is regulatory in nature, focusing on registration fees and securities issuance under incentive plans, not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration, which fits best under the Regulatory Filings (RNS) category as it does not match other specific categories like capital updates or proxy statements.
2026-04-02 English
8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to report unscheduled material events or corporate changes of importance to shareholders. The content focuses on the company's compliance with Nasdaq listing rules, specifically regarding the minimum bid price requirement and the implementation of a reverse stock split to regain compliance. It includes notices from Nasdaq and the Hearings Panel, but does not contain financial statements or detailed financial analysis. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial report. It is a regulatory filing reporting a significant event related to listing compliance. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7836 characters) and detailed event description support this classification with high confidence.
2026-04-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.